Stocktoria
RIGEL PHARMACEUTICALS INC RIGL
RIGEL PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M |
| R&D expense | $33.3M | $23.4M | $24.5M | — | — | — | — | — | — | — |
| SG&A expense | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M | $76.6M | $74.6M | $70.0M | $37.8M | $20.9M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M | -$29.0M | -$69.1M | -$72.7M | -$79.6M | -$69.7M |
| Interest expense | — | $7.9M | $6.9M | $3.7M | $4.9M | $1.4M | $335,000 | — | — | — |
| Income tax | -$245.2M | $881,000 | $0 | — | $605,000 | — | — | $0 | $0 | $0 |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M | -$29.7M | -$66.9M | — | — | — |
| EPS (diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 | $-0.40 | — | — | — |
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M | -$52.2M | -$41.5M | -$58.8M | -$77.6M | -$75.9M |
| Free cash flow | — | — | — | -$74.2M | $5.3M | -$53.4M | -$43.0M | -$59.9M | -$77.7M | -$76.7M |
| Cash & equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M | $30.4M | $22.5M | $76.3M | $38.3M | $17.6M |
| Inventory | $11.5M | $6.0M | $5.5M | $9.1M | $6.6M | $1.6M | $1.4M | $894,000 | — | — |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M | $110.4M | $147.6M | $139.1M | $119.1M | $78.1M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M | — | — | — | — | — |
| Shareholders' equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M | $34.0M | $53.8M | $109.9M | $100.6M | $55.0M |
Growth · year-over-year · Revenue CAGR 34.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +64.1% | +53.4% | -2.8% | -19.4% | +37.4% | +83.2% | +33.2% | +892.6% | -78.0% | — |
| Net income growth | +1999.1% | — | — | — | — | — | — | — | — | — |
| EPS growth | +1867.7% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | -1513.2% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.